Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
19 "Hoon Choi"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
The Roles of Ninjurin1 and Estrogen in Modulating AOM/DSS-Induced Colitis-Associated Colorectal Cancer in Male Mice
Chin-Hee Song, Nayoung Kim, Ryoung Hee Nam, Jae Young Jang, Eun Hye Kim, Sungchan Ha, Eun Shin, Ha-Na Lee, Hoon Choi, Kyu-Won Kim, Sejin Jeon, Goo Taeg Oh
Received October 2, 2024  Accepted January 10, 2025  Published online January 13, 2025  
DOI: https://doi.org/10.4143/crt.2024.959    [Accepted]
AbstractAbstract PDF
Purpose
Ninjury-induced protein 1 (Ninj1) is associated with inflammation and tumor progression and shows increased expression in various cancers. This study aimed to investigate the role of Ninj1 in colitis-associated colorectal cancer (CRC) by focusing on its interaction with 17β-estradiol (E2).
Materials and Methods
Using an azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse model of colitis-associated CRC, wild-type (WT) and Ninj1 knockout (KO) male mice were treated with or without E2.
Results
At week 2, Ninj1 KO mice exhibited attenuated colitis symptoms than WT mice following AOM/DSS treatment. E2 administration significantly alleviated these symptoms in both WT and Ninj1 KO mice, with reductions in the disease activity index (DAI), colon length shortening, and histopathological damage. The levels of pro-inflammatory mediators were reduced by E2 treatment in both groups, with the Ninj1 KO group showing a more pronounced response. At week 13, tumor development in Ninj1 KO mice was significantly lower than that in WT mice, particularly in the distal colon. E2 treatment inhibited tumor formation in WT mice and had a stronger inhibitory effect on distal colon tumorigenesis in Ninj1 KO mice. Immune cell populations, including the populations of macrophages and T cells, were also modulated by E2 in WT mice; however, these effects were diminished in Ninj1 KO mice.
Conclusion
These findings suggest that Ninj1 plays a role in modulating colitis and CRC progression, with E2 exerting anti-inflammatory and anti-tumorigenic effects that are influenced by Ninj1 status.
  • 543 View
  • 40 Download
Close layer
Long-Term Survival Outcomes of Surgical Resection for Lung Adenocarcinoma with Intraoperatively Diagnosed Pleural Metastasis: Target Treatment Era
Yelee Kwon, Jae Kwang Yun, Geun Dong Lee, Se Hoon Choi, Yong-Hee Kim, Hyeong Ryul Kim
Received October 15, 2024  Accepted December 27, 2024  Published online December 30, 2024  
DOI: https://doi.org/10.4143/crt.2024.993    [Accepted]
AbstractAbstract PDF
Purpose
This study aimed to evaluate the clinical impact of main tumor resection on long-term survival compared with pleural biopsy alone in patients with lung adenocarcinoma who were intraoperatively diagnosed with pleural metastasis.
Materials and Methods
A total of 176 patients with adenocarcinoma who had unexpected pleural metastasis detected during surgery from 2002 to 2021 were retrospectively analyzed. Each surgeon decided whether to perform main tumor resection or pleural biopsy alone.
Results
The patients were grouped based on the surgical approaches: main tumor resection (Resection group; n=83) and pleural biopsy only (O&C group; n=93). The Resection group had better overall survival (OS, 10-year survival: 27.9% vs. 9.4%; median survival: 68.3 vs. 36.6 months; p<0.01) and locoregional progression-free survival (10-year survival: 12.5% vs. 7.1%; median survival: 19.6 vs. 10.6 months; p<0.01) than the O&C group. Similar results were found for OS in patients who received tyrosine kinase inhibitors (TKIs) as first-line therapy (10-year survival: 49.2% vs. 15.0%; median survival: 72.2 vs. 45.4 months; p=0.03), patients who did not undergo TKIs treatment (10-year survival: 29.4% vs. 9.2%; median survival: 82.4 vs. 23.8 months; p<0.01), and patients with positive target gene mutation (10-year survival: 31.7% vs. 10.1%; median survival: 72.2 vs. 33.7 months; p<0.01). In multivariate analysis, pleural biopsy only (hazard ratio, 1.73; p=0.04) was a significant predictor of OS.
Conclusion
Main tumor resection can improve survival in patients with lung adenocarcinoma who had unexpected pleural metastasis during operation.
  • 207 View
  • 13 Download
Close layer
Sex-specific Molecular Markers NRF2 and PD-L1 in Colon Carcinogenesis: Implications for Right-sided Colon Cancer
Chin-Hee Song, Yonghoon Choi, Nayoung Kim, Ryoung Hee Nam, Jin Won Kim, Jae Young Jang, Eun Hye Kim, Sungchan Ha, Ha-Na Lee
Received August 22, 2024  Accepted December 26, 2024  Published online December 27, 2024  
DOI: https://doi.org/10.4143/crt.2024.818    [Accepted]
AbstractAbstract PDF
Purpose
This study examined the roles of nuclear factor erythroid 2-related factor 2 (NRF2) and programmed death ligand 1 (PD-L1) in colon carcinogenesis, underscoring on sex and differences in tumor location.
Materials and Methods
A total of 378 participants were enrolled from Seoul National University Bundang Hospital: 88 healthy controls (HC), 139 patients with colorectal adenoma (AD), and 151 patients with colorectal cancer (CRC). Quantitative real-time polymerase chain reaction (PCR), methylation-specific PCR, and immunohistochemistry (IHC) were performed utilizing tumor samples from patients and normal mucosa in the HC group.
Results
NRF2 mRNA expression was higher in the CRC group than in the HC and AD groups, with decreased NRF2 methylation in the AD and CRC groups. NRF2 protein expression, as evaluated by IHC, increased in the AD and CRC groups relative to that in the HC group. PD-L1 protein expression was remarkably higher in the CRC group than in the HC and AD groups. These patterns were consistent in both males and females. In sex- and CRC location-specific analyses, NRF2 methylation was lower in female than in male patients with CRC. NRF2 protein expression was significantly higher in females, particularly in patients with right-sided CRC. Moreover, females exhibited increased PD-L1 mRNA expression compared to males in the AD group, and PD-L1 mRNA levels were higher in females with right-sided CRC than in those with cancer at other locations.
Conclusion
Differences in NRF2 and PD-L1 expression indicate site-specific colon carcinogenesis based on sex, particularly in females with right-sided CRC.
  • 268 View
  • 23 Download
Close layer
Lung and Thoracic cancer
Recurrence Dynamics of Pathological N2 Non–Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor
In Ha Kim, Geun Dong Lee, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Jae Kwang Yun
Cancer Res Treat. 2025;57(1):105-115.   Published online July 23, 2024
DOI: https://doi.org/10.4143/crt.2024.150
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study investigated the recurrence patterns and timing in patients with pathologic N2 (pN2) non-small cell lung cancer (NSCLC) according to the residual tumor (R) descriptor proposed by the International Association for the Study of Lung Cancer (IASLC).
Materials and Methods
From 2004 to 2021, patients with pN2 NSCLC who underwent anatomical resection were analyzed according to the IASLC R criteria using medical records from a single center. Survival analysis was performed using Cox proportional hazards models. Recurrence patterns between complete (R0) and uncertain resections (R[un]) were compared.
Results
In total, 1,373 patients were enrolled in this study: 576 (42.0%) in R0, 286 (20.8%) in R(un), and 511 (37.2%) in R1/R2 according to the IASLC R criteria. The most common reason for R(un) classification was positivity for the highest lymph node (88.8%). In multivariable analysis, the hazard ratios for recurrence in R(un) and R1/R2 compared to R0 were 1.18 (95% confidence interval [CI], 0.96–1.46) and 1.58 (1.31–1.90), respectively. The hazard rate curves displayed similar patterns among groups, peaking at approximately 12 months after surgery. There was a significant difference in distant recurrence patterns between R0 and R(un). Further analysis after stratification with the IASLC N2 descriptor showed significant differences in distant recurrence patterns between R0 and R(un) in patients pN2a1 and pN2a2 disease, but not in those with pN2b disease.
Conclusion
The IASLC R criteria has prognostic relevance in patients with pN2 NSCLC. R(un) is a highly heterogeneous group, and the involvement of the highest mediastinal lymph node can affect distant recurrence patterns.
  • 788 View
  • 51 Download
Close layer
Differences in the Prognostic Impact between Single-Zone and Multi-Zone N2 Node Metastasis in Patients with Station-Based Multiple N2 Non–Small Cell Lung Cancer
Shia Kim, Geun Dong Lee, SeHoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Jae Kwang Yun
Cancer Res Treat. 2025;57(1):95-104.   Published online July 22, 2024
DOI: https://doi.org/10.4143/crt.2024.120
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The International Association for the Study of Lung Cancer suggests further subdivision of pathologic N (pN) category in non–small-cell lung cancer (NSCLC) by incorporating the location and number of involved lymph node (LN) stations. We reclassified patients with the station-based N2b disease into single-zone and multi-zone N2b groups and compared survival outcomes between the groups.
Materials and Methods
This retrospective study included patients with pN2 NSCLC who underwent lobectomy from 2006 to 2019. The N2 disease was subdivided into four categories: single-station N2 without N1 (N2a1), single-station N2 with N1 (N2a2), multiple-station N2 with single zone involvement (single-zone N2b), and multiple-station N2 with multiple zone involvement (multi-zone N2b). LN zones included in the subdivision of N2 disease were upper mediastinal, lower mediastinal, aortopulmonary, and subcarinal.
Results
Among 996 eligible patients, 211 (21.2%), 394 (39.6%), and 391 (39.3%) were confirmed to have pN2a1, pN2a2, and pN2b disease, respectively. In multivariable analysis after adjustment for sex, age, pT category, and adjuvant chemotherapy, overall survival was significantly better with single-zone N2b disease (n=125, 12.6%) than with multi-zone N2b disease (n=266, 26.7%) (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.49 to 0.90; p=0.009) and was comparable to that of N2a2 disease (HR, 1.12; 95% CI, 0.83 to 1.49; p=0.46).
Conclusion
Prognosis of single-zone LN metastasis was better than that of multiple-zone LN metastasis in patients with N2b NSCLC. Along with the station-based N descriptors, zone-based descriptors might ensure optimal staging, enabling the most appropriate decision-making on adjuvant therapy for patients with pN2 NSCLC.
  • 887 View
  • 74 Download
Close layer
Gastrointestinal cancer
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Beodeul Kang, Chan Kim, Hyo Sup Shim, Young Nyun Park, Sanghoon Jung, Sung Hoon Choi, Hye Jin Choi, Choong-kun Lee, Hong Jae Chon
Cancer Res Treat. 2023;55(4):1291-1302.   Published online May 3, 2023
DOI: https://doi.org/10.4143/crt.2022.1450
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy in advanced BTC.
Materials and Methods
Genomic analysis of advanced BTC multi-institutional cohorts was performed using targeted panel sequencing. Genomic alterations were analyzed integrating patients’ clinicopathologic data, including clinical outcomes of Gem/Cis-based therapy. Significance of genetic alterations was validated using clinical next-generation sequencing (NGS) cohorts from public repositories and drug sensitivity data from cancer cell lines.
Results
193 BTC patients from three cancer centers were analyzed. Most frequent genomic alterations were TP53 (55.5%), KRAS (22.8%), ARID1A (10.4%) alterations, and ERBB2 amplification (9.8%). Among 177 patients with BTC receiving Gem/Cis-based chemotherapy, ARID1A alteration was the only independent predictive molecular marker of primary resistance showing disease progression for 1st-line chemotherapy in the multivariate regression model (odds ratio, 3.12; p=0.046). In addition, ARID1A alteration was significantly correlated with inferior progression-free survival on Gem/Cis-based chemotherapy in the overall patient population (p=0.033) and in patients with extrahepatic cholangiocarcinoma (CCA) (p=0.041). External validation using public repository NGS revealed that ARID1A mutation was a significant predictor for poor survival in BTC patients. Investigation of multi-OMICs drug sensitivity data from cancer cell lines revealed that cisplatin-resistance was exclusively observed in ARID1A mutant bile duct cancer cells.
Conclusion
Integrative analysis with genomic alterations and clinical outcomes of the first-line Gem/Cis-based chemotherapy in advanced BTC revealed that patients with ARID1Aalterations showed a significant worse clinical outcome, especially in extrahepatic CCA. Well-designed prospective studies are mandatory to validate the predictive role of ARID1Amutation.

Citations

Citations to this article as recorded by  
  • ARID1A in Gynecologic Precancers and Cancers
    Jaida E. Morgan, Nishah Jaferi, Zainab Shonibare, Gloria S. Huang
    Reproductive Sciences.2024; 31(8): 2150.     CrossRef
  • Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report
    Koji Kameyama, Kosuke Mizutani, Tetsuya Yamada, Seiji Sugiyama, Shingo Kamei, Shigeaki Yokoi, Kengo Matsunaga, Koseki Hirade, Yasutaka Kato, Hiroshi Nishihara, Satoshi Ishihara, Takashi Deguchi
    Molecular and Clinical Oncology.2024;[Epub]     CrossRef
  • A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma
    Wei Zhou, Hao Chi, Xiaohu Zhao, Guangrong Tao, Jianhe Gan
    Clinical and Translational Oncology.2024;[Epub]     CrossRef
  • Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer
    Sohyun Hwang, Seonjeong Woo, Beodeul Kang, Haeyoun Kang, Jung Sun Kim, Sung Hwan Lee, Chang Il Kwon, Dong Soo Kyung, Hwang-Phill Kim, Gwangil Kim, Chan Kim, Hong Jae Chon
    Journal of Hepatology.2024;[Epub]     CrossRef
  • Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors
    Jiumei Zhao, Jing Zhu, Yu Tang, Kepu Zheng, Ziwei Li
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • The role of ARID1A in malignant neoplasms of the female reproductive system: a modern view on diagnostic and therapeutic opportunities
    A. I. Marzaganova, I. R. Martirosyan, A. S. Korchemkina, E. G. Avanesyan, D. A. Korkmazova, O. B. Grakhnova, V. V. Akimina, A. P. Dzhamalutdinova, D. A. Bolloev, A. M. Dugulbgova, Z. G. Bakhmudova, A. T. Salikhova, P. A. Dzigora
    Obstetrics, Gynecology and Reproduction.2024;[Epub]     CrossRef
  • 4,056 View
  • 338 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Lung and Thoracic cancer
The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study
Seong Yong Park, Samina Park, Geun Dong Lee, Hong Kwan Kim, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Tae Hee Hong, Yong Soo Choi, Jhingook Kim, Jong Ho Cho, Young Mog Shim, Jae Ill Zo, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young-Tae Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik
Cancer Res Treat. 2023;55(1):94-102.   Published online June 9, 2022
DOI: https://doi.org/10.4143/crt.2022.290
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.
Materials and Methods
The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.
Results
The mean patient age was 65.29±8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) underwent prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemotherapy (HR, 0.558; p=0.019) were associated with OS.
Conclusion
Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.

Citations

Citations to this article as recorded by  
  • Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
    Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
    Radiotherapy and Oncology.2024; 193: 110123.     CrossRef
  • A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
    Sevcan Atay
    Cancers.2023; 15(21): 5219.     CrossRef
  • 5,801 View
  • 142 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
General
Targeted Liquid Biopsy Using Irradiation to Facilitate the Release of Cell-Free DNA from a Spatially Aimed Tumor Tissue
Jae Myoung Noh, Yeon Jeong Kim, Ho Yun Lee, Changhoon Choi, Won-Gyun Ahn, Taeseob Lee, Hongryull Pyo, Jee Hyun Park, Donghyun Park, Woong-Yang Park
Cancer Res Treat. 2022;54(1):40-53.   Published online May 25, 2021
DOI: https://doi.org/10.4143/crt.2021.151
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We investigated the feasibility of using an anatomically localized, target-enriched liquid biopsy (TLB) in mouse models of lung cancer.
Materials and Methods
After irradiating xenograft mouse with human lung cancer cell lines, H1299 (NRAS proto-oncogene, GTPase [NRAS] Q61K) and HCC827 (epidermal growth factor receptor [EGFR] E746-750del), circulating (cell-free) tumor DNA (ctDNA) levels were monitored with quantitative polymerase chain reaction on human long interspersed nuclear element-1 and cell line-specific mutations. We checked dose-dependency at 6, 12, or 18 Gy to each tumor-bearing mouse leg using 6-MV photon beams. We also analyzed ctDNA of lung cancer patients by LiquidSCAN, a targeted deep sequencing to validated the clinical performances of TLB method.
Results
Irradiation could enhance the detection sensitivity of NRAS Q61K in the plasma sample of H1299-xenograft mouse to 4.5- fold. While cell-free DNA (cfDNA) level was not changed at 6 Gy, ctDNA level was increased upon irradiation. Using double-xenograft mouse with H1299 and HCC827, ctDNA polymerase chain reaction analysis with local irradiation in each region could specify mutation type matched to transplanted cell types, proposing an anatomically localized, TLB. Furthermore, when we performed targeted deep sequencing of cfDNA to monitor ctDNA level in 11 patients with lung cancer who underwent radiotherapy, the average ctDNA level was increased within a week after the start of radiotherapy.
Conclusion
TLB using irradiation could temporarily amplify ctDNA release in xenograft mouse and lung cancer patients, which enables us to develop theragnostic method for cancer patients with accurate ctDNA detection.

Citations

Citations to this article as recorded by  
  • Surpassing sensitivity limits in liquid biopsy
    Tina Moser, Ellen Heitzer
    Science.2024; 383(6680): 260.     CrossRef
  • Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
    Carmen Martin-Alonso, Shervin Tabrizi, Kan Xiong, Timothy Blewett, Sainetra Sridhar, Andjela Crnjac, Sahil Patel, Zhenyi An, Ahmet Bekdemir, Douglas Shea, Shih-Ting Wang, Sergio Rodriguez-Aponte, Christopher A. Naranjo, Justin Rhoades, Jesse D. Kirkpatric
    Science.2024;[Epub]     CrossRef
  • Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer
    Ashley Horne, Ken Harada, Katherine D. Brown, Kevin Lee Min Chua, Fiona McDonald, Gareth Price, Paul Martin Putora, Dominic G. Rothwell, Corinne Faivre-Finn
    Journal of Thoracic Oncology.2024; 19(8): 1164.     CrossRef
  • Modulating cell-free DNA biology as the next frontier in liquid biopsies
    Shervin Tabrizi, Carmen Martin-Alonso, Kan Xiong, Sangeeta N. Bhatia, Viktor A. Adalsteinsson, J. Christopher Love
    Trends in Cell Biology.2024;[Epub]     CrossRef
  • Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?
    Benedetta Cena, Emmanuel Melloul, Nicolas Demartines, Olivier Dormond, Ismail Labgaa
    International Journal of Molecular Sciences.2022; 23(10): 5343.     CrossRef
  • Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden
    Kwang Seob Lee, Jieun Seo, Choong-Kun Lee, Saeam Shin, Zisun Choi, Seungki Min, Jun Hyuek Yang, Woo Sun Kwon, Woobin Yun, Mi Ri Park, Jong Rak Choi, Hyun Cheol Chung, Seung-Tae Lee, Sun Young Rha
    Clinical Chemistry.2022; 68(12): 1519.     CrossRef
  • 6,985 View
  • 285 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database
Bum Sik Tae, Byung Jo Jeon, Seung Hun Shin, Hoon Choi, Jae Hyun Bae, Jae Young Park
Cancer Res Treat. 2019;51(2):593-602.   Published online July 18, 2018
DOI: https://doi.org/10.4143/crt.2018.119
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the association of androgen deprivation therapy (ADT) with cognitive dysfunction.
Materials and Methods
Using the National Health Insurance Service database of the entire Korean adult prostate cancer population (n=236,391), data on ADT and cognitive dysfunction between 2008 and 2015 were analyzed. We excluded patients previously diagnosed with cognitive dysfunction, dementia, or a cerebral event history. We tested the effect of ADT on the risk of cognitive dysfunction using propensity score–matched Cox proportional hazards regression models and Kaplan-Meier survival analysis. Our final cohort comprised of 35,401 individuals with prostate cancer, including 24,567 men (70.6%) who underwent ADT.
Results
During a mean follow-up period of 4.1 years, 4,741 patients were newly diagnosed with cognitive dysfunction. A statistically significant association was found between ADT and the risk of cognitive dysfunction (hazard ratio, 1.169; p=0.002). Meanwhile, age (≥ 70 years), diabetes, hypertension, cardiovascular history, and peripheral vascular disease were identified as factors that contribute to the increased risk of cognitive dysfunction. In contrast, the use of statins and aspirin was associated with a lower risk of cognitive dysfunction. Kaplan-Meier analysis demonstrated that patients aged 70 years or older who underwent ADT had the lowest cumulative probability of remaining cognitive dysfunction-free (log-rank p < 0.001).
Conclusion
Our results revealed an association between the use of ADT for the treatment of prostate cancer and an increased risk of cognitive dysfunction in a nationwide population-based study. This finding should be further evaluated in prospective studies.

Citations

Citations to this article as recorded by  
  • Unraveling the bidirectional link between cancer and dementia and the impact of cancer therapies on dementia risk: A systematic review and meta‐analysis
    Liwei Ma, Edwin C. K. Tan, Benjamin Goudey, Liang Jin, Yijun Pan
    Alzheimer's & Dementia.2025;[Epub]     CrossRef
  • Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis
    David E. Hinojosa-Gonzalez, Affan Zafar, Gal Saffati, Shane Kronstedt, Dimitar V. Zlatev, Mohit Khera
    Prostate Cancer and Prostatic Diseases.2024; 27(3): 507.     CrossRef
  • Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
    Viswanath Das, John H. Miller, Charanraj Goud Alladi, Narendran Annadurai, Juan Bautista De Sanctis, Lenka Hrubá, Marián Hajdúch
    Medicinal Research Reviews.2024; 44(5): 2078.     CrossRef
  • Cognitive effects of long‐term androgen deprivation therapy in older men with prostate cancer
    Denise Pergolizzi, Kathleen R. Flaherty, Rebecca M. Saracino, James C. Root, Elizabeth Schofield, Caroline Cassidy, Vani Katheria, Sunita K. Patel, William Dale, Christian J. Nelson
    Psycho-Oncology.2024;[Epub]     CrossRef
  • Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review
    Lorna Pembroke, Kerry A. Sherman, Heather Francis, Haryana M. Dhillon, Howard Gurney, David Gillatt
    Neuropsychology Review.2024;[Epub]     CrossRef
  • Androgen deprivation therapy exacerbates Alzheimer’s-associated cognitive decline via increased brain immune cell infiltration
    Chao Zhang, Mae Aida, Shalini Saggu, Haiyan Yu, Lianna Zhou, Hasibur Rehman, Kai Jiao, Runhua Liu, Lizhong Wang, Qin Wang
    Science Advances.2024;[Epub]     CrossRef
  • Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies
    Meng-fan Cui, Li-ming Chen, Cindy Jiang, Bing-zhe Ma, Fu-wen Yuan, Chen Zhao, Shi-min Liu
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Urogeriatrisches Denken am Beispiel der antiandrogenen Therapie des Prostatakarzinoms
    A. Wiedemann, A. Manseck, J. Stein, M. Fröhner, C. Fiebig, A. Piotrowski, R. Kirschner-Hermanns
    Die Urologie.2024; 63(9): 867.     CrossRef
  • Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease
    Rachel M. Barker, Alfie Chambers, Patrick G. Kehoe, Edward Rowe, Claire M. Perks
    Clinical Science.2024; 138(21): 1357.     CrossRef
  • A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors
    Charlotte Kerstens, Hans P. M. W. Wildiers, Gwen Schroyen, Mercedes Almela, Ruth E. Mark, Maarten Lambrecht, Sabine Deprez, Charlotte Sleurs
    Cancers.2023; 15(4): 1215.     CrossRef
  • Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial
    Steven C. R. Williams, Ndaba Mazibuko, Owen O’Daly, Christian Zurth, Fiona Patrick, Christian Kappeler, Iris Kuss, Patricia E. Cole
    Targeted Oncology.2023; 18(3): 403.     CrossRef
  • Does ADT Influence the Risk of Suicidal Ideation among US Veteran Prostate Cancer Patients Pre-Exposed to PTSD?
    Smit Brahmbhatt, Herta H. Chao, Shiv Verma, Sanjay Gupta
    Cancers.2023; 15(10): 2739.     CrossRef
  • Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
    Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Jin Seon Cho
    Prostate International.2022; 10(1): 68.     CrossRef
  • Impact of Testosterone on Alzheimer’s Disease
    Vittorio Emanuele Bianchi
    The World Journal of Men's Health.2022; 40(2): 243.     CrossRef
  • Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer
    Gregory L. Branigan, Georgina Torrandell‐Haro, Maira Soto, Edward P. Gelmann, Francesca Vitali, Kathleen E. Rodgers, Roberta Diaz Brinton
    Cancer Medicine.2022; 11(13): 2687.     CrossRef
  • Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
    Jeffrey S. Wefel, Charles J. Ryan, Julie Van, James C. Jackson, Alicia K. Morgans
    CNS Drugs.2022; 36(5): 419.     CrossRef
  • The Insignificant Correlation between Androgen Deprivation Therapy and Incidence of Dementia Using an Extension Survival Cox Hazard Model and Propensity-Score Matching Analysis in a Retrospective, Population-Based Prostate Cancer Registry
    Young Ae Kim, Su-Hyun Kim, Jae Young Joung, Min Soo Yang, Joung Hwan Back, Sung Han Kim
    Cancers.2022; 14(11): 2705.     CrossRef
  • Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
    David Conde-Estévez, Iván Henríquez, Jesús Muñoz-Rodríguez, Alejo Rodriguez-Vida
    Expert Opinion on Drug Metabolism & Toxicology.2022; 18(9): 601.     CrossRef
  • Testosterone and Alzheimer’s disease
    K. O. Kuznetsov, R. R. Khaidarova, R. H. Khabibullina, E. S. Stytsenko, V. I. Filosofova, I. R. Nuriakhmetova, E. M. Hisameeva, G. S. Vazhorov, F. R. Khaibullin, E. A. Ivanova, K. V. Gorbatova
    Problems of Endocrinology.2022; 68(5): 97.     CrossRef
  • Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis
    Haiying Cui, Yao Wang, Fei Li, Guangyu He, Zongmiao Jiang, Xiaokun Gang, Guixia Wang
    Prostate Cancer and Prostatic Diseases.2021; 24(1): 15.     CrossRef
  • Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors
    Alicia K. Morgans, Joseph Renzulli, Kara Olivier, Neal D. Shore
    Clinical Genitourinary Cancer.2021; 19(5): 467.e1.     CrossRef
  • Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
    Jui-Ming Liu, Chin-Yao Shen, Wallis C. Y. Lau, Shih-Chieh Shao, Kenneth K. C. Man, Ren-Jun Hsu, Chun-Te Wu, Edward Chia-Cheng Lai
    Cancers.2021; 13(15): 3861.     CrossRef
  • Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function
    A. B. Reiss, U. Saeedullah, D. J. Grossfeld, A. D. Glass, A. Pinkhasov, A. E. Katz
    Clinical and Translational Oncology.2021; 24(5): 733.     CrossRef
  • Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
    Vérane Achard, Kelly Ceyzériat, Benjamin B. Tournier, Giovanni B. Frisoni, Valentina Garibotto, Thomas Zilli
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study
    Niamh L Mundell, Patrick J Owen, Jack Dalla Via, Helen Macpherson, Robin M Daly, Steve F Fraser
    BMJ Open.2021; 11(12): e058478.     CrossRef
  • Antiaging Therapies, Cognitive Impairment, and Dementia
    Devin Wahl, Rozalyn M Anderson, David G Le Couteur, Rafael de Cabo
    The Journals of Gerontology: Series A.2020; 75(9): 1643.     CrossRef
  • A review of prostate cancer treatment impact on the CNS and cognitive function
    Charles Ryan, Jeffrey S. Wefel, Alicia K. Morgans
    Prostate Cancer and Prostatic Diseases.2020; 23(2): 207.     CrossRef
  • Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea
    Young-Jae Hwang, Seon Mee Park, Soomin Ahn, Jongchan Lee, Young Soo Park, Nayoung Kim
    Hepatobiliary & Pancreatic Diseases International.2020; 19(6): 575.     CrossRef
  • WITHDRAWN: The Changes of ADC Value, DCE-MRI Parameters and Their Influence on Neuropsychology in Prostate Cancer Patients after Endocrine Therapy Based on Magnetic Resonance Imaging
    Yang Lu, Shang Ge, Yan Liu, Gengji Bai
    Neuroscience Letters.2020; : 135221.     CrossRef
  • Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician
    Aisha L. Siebert, Leiszle Lapping-Carr, Alicia K. Morgans
    European Urology Focus.2020; 6(6): 1170.     CrossRef
  • An Updated Review: Androgens and Cognitive Impairment in Older Men
    Zhonglin Cai, Hongjun Li
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study
    Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Seong Soo Jeon, Hanjong Ahn, Young-Su Ju, Jin Seon Cho, Gianluigi Forloni
    PLOS ONE.2020; 15(12): e0244660.     CrossRef
  • Androgen deprivation therapy for prostate cancer and risk of dementia
    David Robinson, Hans Garmo, Mieke Van Hemelrijck, Jan‐Erik Damber, Ola Bratt, Lars Holmberg, Lars‐Olof Wahlund, Pär Stattin, Jan Adolfsson
    BJU International.2019; 124(1): 87.     CrossRef
  • Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer
    Nirmish Singla, Rashed A. Ghandour, Ganesh V. Raj
    Expert Opinion on Investigational Drugs.2019; 28(3): 249.     CrossRef
  • Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis
    Omar Saeed, Lori J. Bernstein, Rouhi Fazelzad, Mary Samuels, Lynn A. Burmeister, Lehana Thabane, Shereen Ezzat, David P. Goldstein, Jennifer Jones, Anna M. Sawka
    Journal of Cancer Survivorship.2019; 13(2): 231.     CrossRef
  • Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study
    Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park
    Cancer Medicine.2019; 8(9): 4475.     CrossRef
  • 9,365 View
  • 293 Download
  • 37 Web of Science
  • 36 Crossref
Close layer
Medical Travel among Non-Seoul Residents to Seek Prostate Cancer Treatment in Medical Facilities of Seoul
Jae Heon Kim, So Young Kim, Seok-Joong Yun, Jae Il Chung, Hoon Choi, Ho Song Yu, Yun-Sok Ha, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun-Jae Kim, Jong-Hyock Park, Ji Youl Lee
Cancer Res Treat. 2019;51(1):53-64.   Published online February 20, 2018
DOI: https://doi.org/10.4143/crt.2017.468
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aims to investigate the trend in medical travel by non-Seoul residents to Seoul for treatment of prostate cancer and also to investigate the possible factors affecting the trend.
Materials and Methods
This study represents a retrospective cohort study using data from theKoreanNationalHealth Insurance System from 2002 to 2015. Annual trends were produced for proportions of patients who traveled according to the age group, economic status and types of treatment. Multiple logistic analysiswas used to determine factors affecting surgeries at medical facilities in Seoul among the non-Seoul residents.
Results
A total of 68,543 patients were defined as newly diagnosed prostate cancer cohorts from 2005 to 2014. The proportion of patients who traveled to Seoul for treatment, estimated from cases with prostate cancer-related claims, decreased slightly over 9 years (28.0 at 2005 and 27.0 at 2014, p=0.02). The average proportion of medical travelers seeking radical prostatectomy increased slightly but the increase was not statistically significant (43.1 at 2005 and 45.4 at 2014, p=0.26). Income level and performance ofrobot-assisted radical prostatectomy were significant positive factors for medical travel to medical facilities in Seoul. Combined comorbidity diseases and year undergoing surgery were significant negative factors for medical travel to medical facilities in Seoul.
Conclusion
The general trend of patients travelling from outside Seoul for prostate cancer treatment decreased from 2005 to 2014. However, a large proportion of traveling remained irrespective of direct distance from Seoul.

Citations

Citations to this article as recorded by  
  • Relationship between patient outcomes and patterns of fragmented cancer care in older adults with gastric cancer: A nationwide cohort study in South Korea
    Dong-Woo Choi, Seungju Kim, Sun Jung Kim, Dong Wook Kim, Kwang Sun Ryu, Jae Ho Kim, Yoon-Jung Chang, Kyu-Tae Han
    Journal of Geriatric Oncology.2024; 15(2): 101685.     CrossRef
  • Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study
    Seong Cheol Kim, Seungbong Han, Ji Hyung Yoon, Sungchan Park, Kyung Hyun Moon, Sang Hyeon Cheon, Gyung-Min Park, Taekmin Kwon
    Investigative and Clinical Urology.2024; 65(2): 124.     CrossRef
  • Domestic medical travel from non-Seoul regions to Seoul for initial breast cancer treatment: a nationwide cohort study
    Jae Ho Jeong, Jinhong Jung, Hee Jeong Kim, Jong Won Lee, Beom-Seok Ko, Byung Ho Son, Kyung Hae Jung, Il Yong Chung
    Annals of Surgical Treatment and Research.2023; 104(2): 71.     CrossRef
  • Symptom Experiences before Medical Help-Seeking and Psychosocial Responses of Patients with Esophageal Cancer: A Qualitative Study
    Hui Ge, Liang Zhang, Xuanxuan Ma, Wen Li, Shuwen Li, Pranshu Sahgal
    European Journal of Cancer Care.2023; 2023: 1.     CrossRef
  • Cancer care patterns in South Korea: Types of hospital where patients receive care and outcomes using national health insurance claims data
    Dong‐Woo Choi, Sun Jung Kim, Seungju Kim, Dong Wook Kim, Wonjeong Jeong, Kyu‐Tae Han
    Cancer Medicine.2023; 12(13): 14707.     CrossRef
  • Regional disparities in the availability of cancer clinical trials in Korea
    Jieun Jang, Wonyoung Choi, Sung Hoon Sim, Sokbom Kang
    Epidemiology and Health.2023; 46: e2024006.     CrossRef
  • Do Patients Residing in Provincial Areas Transport and Spend More on Cancer Treatment in Korea?
    Woorim Kim, Kyu-Tae Han, Seungju Kim
    International Journal of Environmental Research and Public Health.2021; 18(17): 9247.     CrossRef
  • Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis
    Hyun Young Lee, Do Kyoung Kim, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Bora Lee, Jae Heon Kim
    Cancer Research and Treatment.2020; 52(1): 301.     CrossRef
  • Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015
    Hyun Young Lee, Suyeon Park, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Jae Heon Kim
    Yonsei Medical Journal.2019; 60(3): 257.     CrossRef
  • Why is Life Expectancy in Busan Shorter than in Seoul? Age and Cause-Specific Contributions to the Difference in Life Expectancy between Two Cities
    Young-Ho Khang, Jinwook Bahk
    Yonsei Medical Journal.2019; 60(7): 687.     CrossRef
  • 10,860 View
  • 229 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Case Report
A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
Cancer Res Treat. 2016;48(1):409-414.   Published online February 17, 2015
DOI: https://doi.org/10.4143/crt.2014.299
AbstractAbstract PDFPubReaderePub
von Hippel–Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome associated with mutations of the VHL tumor suppressor gene located on chromosome 3p25. The loss of functional VHL protein contributes to tumorigenesis. This condition is characterized by development of benign and malignant tumors in the central nervous system (CNS) and the internal organs, including kidney, adrenal gland, and pancreas. We herein describe the case of a 74-year-old man carrying the VHL gene mutation who was affected by simultaneous colorectal adenocarcinoma, renal clear cell carcinoma, and hemangioblastomas of CNS.

Citations

Citations to this article as recorded by  
  • Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review
    Yanlei Wang, Zhaoxiang Liu, Wenhui Zhao, Chenxiang Cao, Luqi Xiao, Jianzhong Xiao
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1611.     CrossRef
  • Sporadic Renal Hemangioblastoma: A Case Report of a Rare Entity
    Fnu Raja, Vinesh Kumar, Azzam Hammad, Caroline Abramovich
    Cureus.2023;[Epub]     CrossRef
  • VHL syndrome without clear family history: A rare case report and literature review of Chinese patients
    Yaheng Li, Xiaohong Xin, Wenzhu Song, Xuan Zhang, Shengli Chen, Qian Wang, Aizhong Li, Yafeng Li
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Von Hipple-Lindau disease complicated with central retinal vein occlusion: a case report
    Xingwang Chen, Mengyao Wang, Yuan Tang, Bing Xie, Xiaomei Nie, Shanjun Cai
    BMC Ophthalmology.2022;[Epub]     CrossRef
  • Whole-Exome Sequencing Reveals Novel Variations in Patients with Familial Von Hippel−Lindau Syndrome
    Yuhao Zhou, Jian Liu, Liangzhao Chu, Minghao Dong, Luqian Feng
    World Neurosurgery.2021; 150: e696.     CrossRef
  • Sporadic renal hemangioblastoma: A case report of a rare benign renal tumor
    Lukas Oberhammer, Michael Josef Mitterberger, Lukas Lusuardi, Thomas Kunit, Martin Drerup, Daniela Colleselli, Hubert Griessner, Martina Hager
    Clinical Case Reports.2019; 7(12): 2321.     CrossRef
  • MicroRNA Assisted Gene Regulation in Colorectal Cancer
    Adewale Fadaka, Ashley Pretorius, Ashwil Klein
    International Journal of Molecular Sciences.2019; 20(19): 4899.     CrossRef
  • 12,858 View
  • 101 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Original Articles
Biopsy Related Prostate Status Does Not Affect on the Clinicopathological Outcome of Robotic Assisted Laparoscopic Radical Prostatectomy
Hoon Choi, Young Hwii Ko, Sung Gu Kang, Seok Ho Kang, Hong Seok Park, Jun Cheon, Vipul R. Patel
Cancer Res Treat. 2009;41(4):205-210.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.205
AbstractAbstract PDFPubReaderePub
Purpose

To determine whether the biopsy core number and time interval between prostate biopsy and radical prostatectomy affect the operative and oncologic outcome of robot assisted laparoscopic radical prostatectomy (RALP).

Materials and Methods

From January 2008 to April 2009, a single surgeon performed 72 RALPs after an initial learning period of 30 cases. The relationship between time from biopsy to prostatectomy and biopsy core number with operative time and estimated blood loss (EBL) were initially evaluated with a linear regression model. These patients were classified into groups according to whether the interval from biopsy to RALP was within four weeks or not, and whether there were less than or greater than 10 core specimens removed.

Results

RALP was performed in 34 patients within four weeks of biopsy, and in 38 patients more than 4 weeks after biopsy. According to the number of core specimens removed, less than 10 cores were performed in 10 patients, and more than 10 cores were performed in 62 patients. Using an interval of 4 weeks as the cutoff point, early surgery was associated with longer operating time (232.6 vs 208.8 min) and increased estimated blood loss (305.1 vs 276.9 mL). For cases with more than 10 biopsy cores, there was a slight increase in operative time (229.2 vs 210.3 min). None of these differences were statistically significant by multivariate analysis.

Conclusion

Our data suggests that there is no reason to delay RALP to more than 4 weeks after prostate biopsy. It also revealed that the number of biopsy cores (up to 14) did not influence operative outcome. Thus, RALP is a feasible procedure regardless of the biopsy related prostate state.

Citations

Citations to this article as recorded by  
  • Effect of Transperineal Versus Transrectal Prostate Biopsy on the Quality of Hydrogel Spacer Placement in Men Prior to Radiation Therapy for Prostate Cancer
    Michael E. Rezaee, Ulysses Gardner, Mark N. Alshak, Stephen C. Greco, Daniel Y. Song, Michael Goldstein, Christian P. Pavlovich
    Urology.2023; 182: 27.     CrossRef
  • Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis
    Jie Li, Qing Jiang, Qiubo Li, Yuanfeng Zhang, Liang Gao
    International Urology and Nephrology.2020; 52(4): 619.     CrossRef
  • Short interval of biopsy to robotic-assisted laparoscopic radical prostatectomy does not render any adverse effects on the perioperative outcomes
    Minke He, Yaohui Li, Zhuoyi Xiang, Li-an Sun, Yanjun Zhu, Xiaoyi Hu, Jianming Guo, Hang Wang
    Medicine.2018; 97(36): e11686.     CrossRef
  • A Multidimensional Analysis of Prostate Surgery Costs in the United States: Robotic-Assisted versus Retropubic Radical Prostatectomy
    Akash Bijlani, April E. Hebert, Mike Davitian, Holly May, Mark Speers, Robert Leung, Nihal E. Mohamed, Henry S. Sacks, Ashutosh Tewari
    Value in Health.2016; 19(4): 391.     CrossRef
  • Interval from Prostate Biopsy to Radical Prostatectomy Does Not Affect Immediate Operative Outcomes for Open or Minimally Invasive Approach
    Bumsoo Park, Seol Ho Choo, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi
    Journal of Korean Medical Science.2014; 29(12): 1688.     CrossRef
  • Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
    In Sung Kim, Woong Na, Jung Su Nam, Jong Jin Oh, Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Sang Eun Lee
    Korean Journal of Urology.2011; 52(10): 664.     CrossRef
  • Prostate-Specific Antigen Density as a Powerful Predictor of Extracapsular Extension and Positive Surgical Margin in Radical Prostatectomy Patients with Prostate-Specific Antigen Levels of Less than 10 ng/ml
    Jin-Seok Chang, Hoon Choi, Young-Seop Chang, Jin-Bum Kim, Mi Mi Oh, Du Geon Moon, Jae Hyun Bae, Jun Cheon
    Korean Journal of Urology.2011; 52(12): 809.     CrossRef
  • 9,500 View
  • 51 Download
  • 7 Crossref
Close layer
Docetaxel and Cisplatin Combination Chemotherapy in Patients with Squamous Cell Carcinomas of the Head and Neck
Jung Hyun Lee, Kyung Woo Lee, Young Jin Choi, Jae Hoon Choi, Ho Jin Shin, Joo Seop Chung, Goon Jae Cho, Byung Ju Lee, Soo Geun Wang
Cancer Res Treat. 2003;35(3):261-266.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.261
AbstractAbstract PDF
PURPOSE
The objective of this phase II study was to assess the clinical antitumor activity and toxicities of docetaxel and cisplatin chemotherapy, in patients with locally advanced and metastatic, recurrent squamous cell carcinomas of the head and neck (SCCHN). MATERIALS AND METHODS: All eligible patients with locally advanced and metastatic, recurrent SCCHN had received two courses of chemotherapy followed by repeated head and neck examinations and computed tomography. Patients who had received prior chemotherapy with taxanes were ineligible. If the patients achieved a response (either CR or PR), they received one more course of chemotherapy prior to undergoing definitive local treatment. The combination chemotherapy consisted of docetaxel, 70 mg/m2, and cisplatin, 75 mg/m2, on day 1, with the cycles repeated every 3~4 weeks. RESULTS: All 32 patients were assessable for response and toxicity analyses. The most common grade 3/4 adverse event was neutropenia, which occurred in 11% of cases. No febrile neutropenia was noticed. The other grade 3/4 adverse events included: anemia (2%) and stomatitis (3%). The response rate in patients with locally advanced cancer was 19/21 (90%). Fifteen patients (71%) achieved a CR and 4 (19%) a PR. Out of the 4 patients presenting with a distant metastatic disease, 1 each achieved CR and PR, with 2 stable disease (SD). Out of the 7 patients with a recurrence at a distant site, 1 each achieved PR and SD, and 5 (71%) had a progression of the disease (PD). The overall response rate was 22/32 (69%).
CONCLUSION
Docetaxel plus cisplatin is an effective regimen with an acceptable toxicity profile. This regimen may offer high antitumor activity on short outpatient administration, with a low incidence of severe toxicity.

Citations

Citations to this article as recorded by  
  • The Analysis of Induction Chemotherapy Using Docetaxel and Platinum in Treatment of Hypopharyngeal Carcinoma
    Jongseung Kim, Kyengsuk Lee, Byungeon Hwang, Sangho Lim, Sunho Ryu, Ilwoo Ha, Eun Jung Lee, Kihwan Hong, Yunsu Yang
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2010; 53(11): 706.     CrossRef
  • The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
    Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung
    Cancer Research and Treatment.2007; 39(3): 93.     CrossRef
  • 5,091 View
  • 21 Download
  • 2 Crossref
Close layer
Detection of p16(INK4A) in the Mixed Cell Populations of Normal Peripheral Blood Mononuclear Cells and Cervical Cancer Cell Lines
Ji Young Kwon, Yoon Sung Jo, Ye Hoon Choi, Jong Gyu Chang, Ki Sung Ryu, Jong Gu Rha, Ku Taek Han
Cancer Res Treat. 2003;35(3):254-260.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.254
AbstractAbstract PDF
PURPOSE
Human papilloma viruses (HPVs) play a central role in the pathogenesis of neoplastic lesions of the uterine cervix. The viral oncoprotein HPV E6 degrades the p53 protein, and the HPV E7 protein inactivates pRB and increases the expression of the CDK inhibitor, p16(INK4A). We investigated the usefulness of p16(INK4A) as a biologic marker for the cervical dysplastic and neoplastic cells.
MATERIALS AND METHODS
We examined the expression of p16(INK4A) and cytokeratin in a mixed population of normal peripheral blood mononuclear cells (PBMC) and the cervical cancer cell lines (HeLa, SiHa, and CasKi) using flow cytometry. RESULTS: The DNA indices of the HeLa, SiHa and CasKi cell lines were 1.89, 1.53 and 1.75, respectively, indicating that these cells are aneuploid cells. Furthermore, the positive rate of p16(INK4A) expression was 86.7% for the HeLa mixed population, 85.6% for the SiHa mixed population, and 92.2% for the CasKi mixed population. According to the FL3A vs FL3W histogram, electrical gating of the HeLa, SiHa and CasKi mixed populations showed the expression levels of both cytokeratin and p16(INK4A) to be identical, at 86.6%, 84.8% and 85.0%, respectively. These findings revealed that almost all cells selected through electrical gating were cervical cancer cells originating from the epithelium and which expressed cytokeratin and p16(INK4A). On the other hand, when each mixed population was electrically gated for normal PBMC, we found that the PBMCs expressed neither cytokeratin nor p16(INK4A).
CONCLUSION
Using flow cytometry, we observed the enhanced expression of p16(INK4A) in cervical cancer cell lines. These RESULTS suggest the usefulness of p16(INK4A) for the selective detection of cervical dysplastic and cancer cells in the liquid-based samples, which are taken from the cervices and contaminated with blood and stromal cells.

Citations

Citations to this article as recorded by  
  • 2-Methoxyestradiol: A Hormonal Metabolite Modulates Stimulated T-Cells Function and proliferation
    J.G.Y. Luc, R. Paulin, J.Y. Zhao, D.H. Freed, E.D. Michelakis, J. Nagendran
    Transplantation Proceedings.2015; 47(6): 2057.     CrossRef
  • 4,493 View
  • 76 Download
  • 1 Crossref
Close layer
Comparative study of survival rate of gastric cancer patients according to TNM classification
Chang Hoon Lee, Kyung Hoon Choi, Jae Kwan Seo
J Korean Cancer Assoc. 1993;25(2):170-175.
AbstractAbstract PDF
No abstract available.
  • 2,338 View
  • 13 Download
Close layer
A 20 years, experience with well differentiated thyroid carcinoma in children & teenagers
Jae Sub Park, Seung Hoon Choi, Eu Ho Hwang
J Korean Cancer Assoc. 1991;23(3):640-647.
AbstractAbstract PDF
No abstract available.
  • 2,243 View
  • 13 Download
Close layer
A case of congenital mesoblastic nephroma-diagnosed during intrauterine life
Jeong Lim Kim, Chuhl Joo Lyu, Ki Soo Pai, Chul Lee, Pyung Kil Kim, Byung Soo Kim, Kook Lee, Ki Keun Oh, Seung Hoon Choi, Woo Hee Jung
J Korean Cancer Assoc. 1991;23(2):458-464.
AbstractAbstract PDF
No abstract available.
  • 2,657 View
  • 13 Download
Close layer
Effect of Retinoic Acid on the Growth of Subcutaneously Injected C1300 Neuroblastoma and on the Survival of the Host A / J Mice
Hee Boong Park, Byeong Jun, Seung Hoon Choi
J Korean Cancer Assoc. 1994;26(1):113-119.
AbstractAbstract PDF
Deficiency of vitamin A and/or its precursors has been associated with increased cancer risk in animals and humans. Therapeutic trials of vitamin A and related compounds(retinoids) have demonstrated activities in several cancerous and precancerous conditions. We measured the effects of a retinoic acid on the growth of subcutaneously injected C1300 neuroblastoma and on the survival of the host A/J mice. The fifty A/J mice were inoculated with 10' of C- 1300 neuroblastoma cell in the right back. They were divided into five groups. One group received saline as a control. Two groups recieved 2 mg/kg and 5 mg/kg of retinoic acid. The other two groups recieved low dose(50 mg/kg and 100 mg/kg) cysclophosphamide. Tumor volume and survival were assessed. The survivals were significantly increased(p<0.05) in three groups, mice recieved 5 mg/kg of retinoic acid, 50 mg/kg and 100 mg/kg of cyclophosphamide. Tumor volumes of the mice treated with 5 mg/kg of retinoic acid were significantly lower than the control group(p<0.05). Retinoic acid suppressed the growth of neuroblastoma, it increased the survival of the treated mice if adequate doses were used.
  • 2,240 View
  • 17 Download
Close layer
Effects of natural Killer Cell Manupulation on the Metastatic Cancer and Host Immune Response
Seung Hoon Choi
J Korean Cancer Assoc. 1996;28(2):368-375.
AbstractAbstract PDF
The purpose of this study was to determine the susceptibility of murine Cl300 neuroblstoma to in vivo natural killer(NK) cell mediated cytolysis and to determine if NK cells influence metastasis of this tumor. The role of NK cells in controlling the metastasis af C1300 neuroblastama to the lung was examined in A/J mice. Treatment with Interleukin-2 on days 1 through 5 after C1300 inoculation significantly decreased the tumor growth, inhibited pulmonary metastasis, and enhanced in vitro NK killing of YAC-l.Treatment with gamma Interferon on days 1 through 5 after tumuor inoculation significantly inhibited pulmonary metastasis. Antitumor effects of Interleukin-2 was stronger than that of gamma Interferon. In vivo depletion of NK cells with anti-asialo GMl significantly enhanced tumor growth and decreased host antitumor activity. These results demonstrated that in vivo elinimation of anti-asialo GM1 positive cells increased pulmonary metastasis, and in such mice, there were significant differences in metastatic potential between control and Interleukin-2, gamma Interferon treated groups.
  • 2,647 View
  • 19 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP